Aim: This study evaluates the diagnostic performance of the novel blood-based device, LIVERFASt to detect fibrosis stages in patients with metabolic […]
The poster presents a retrospective study on the use of non-invasive tests (NITs) to initiate and monitor Resmetirom (RT) therapy
In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4
This publication evaluates the real-world use of non-invasive tests (LIVERFASt, FIB-4, and VCTE) in monitoring MASH patients undergoing resmetirom therapy.
This publication explores the relationship between psoriasis severity and liver steatosis using the AI-based LIVERFASt tool. Patients with more severe
Combining LIVERSTAT with Liver Stiffness Measurement (LSM) more effectively identifies advanced liver fibrosis (F3F4) in patients with MASLD, particularly those
Combining LIVERFASt with Liver Stiffness Measurement (LSM) is more effective than FIB-4 & LSM for identifying advanced liver fibrosis in
This publication introduces LIVERFASt, a non-invasive biomarker for predicting liver steatosis and fibrosis in patients with chronic Hepatitis B and
MASLD affects more than 25% of subjects of the general population and can progress to advanced fibrosis (AF) and cirrhosis
Hepatitis C virus (HCV) infection is a common cause of both liver cirrhosis and hepatocellular carcinoma. Successful Direct antiviral agents